Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells.
about
The role of urotensin II in cardiovascular and renal physiology and diseasesNox family NADPH oxidases in mechano-transduction: mechanisms and consequencesBiochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular systemTGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunitiesUpregulation of Nox4 in the aging vasculature and its association with smooth muscle cell polyploidyThe G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.NADPH oxidases in vascular pathology.A Novel Urotensin II Receptor Antagonist, KR-36996 Inhibits Smooth Muscle Proliferation through ERK/ROS Pathway.NADPH oxidases: functions and pathologies in the vasculature.Regulation of NADPH oxidase in vascular endothelium: the role of phospholipases, protein kinases, and cytoskeletal proteins.Role of Nox4 and Nox2 in hyperoxia-induced reactive oxygen species generation and migration of human lung endothelial cells.Essential hypertension and oxidative stress: New insightsThe NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1.Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosisDocosahexaenoic acid inhibits UVB-induced activation of NF-κB and expression of COX-2 and NOX-4 in HR-1 hairless mouse skin by blocking MSK1 signaling.NOX4 mediates BMP4-induced upregulation of TRPC1 and 6 protein expressions in distal pulmonary arterial smooth muscle cellsIs peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?Urotensin II inhibits skeletal muscle glucose transport signaling pathways via the NADPH oxidase pathway.Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy.Potential Clinical Implications of the Urotensin II Receptor Antagonists.Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S PathwayUrotensin-II-Mediated Reactive Oxygen Species Generation via NADPH Oxidase Pathway Contributes to Hepatic Oval Cell ProliferationNox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy.The NOX toolbox: validating the role of NADPH oxidases in physiology and disease.NADPH oxidase-derived reactive oxygen species in cardiac pathophysiologyTLR4 regulates pulmonary vascular homeostasis and remodeling via redox signaling.A closer look at the role of urotensin II in the metabolic syndrome.NADPH oxidase 4 is required for interleukin-1β-mediated activation of protein kinase Cδ and downstream activation of c-jun N-terminal kinase signaling in smooth muscle.Regulation of ROS signal transduction by NADPH oxidase 4 localization.Urotensin II-induced insulin resistance is mediated by NADPH oxidase-derived reactive oxygen species in HepG2 cells.Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-{beta}1 and insulin-like growth factor binding protein-3.Expression, localization, and function of the thioredoxin system in diabetic nephropathy.Blockade of Urotensin II Receptor Prevents Vascular Dysfunction.PPARgamma as a potential therapeutic target in pulmonary hypertension.Role of urotensin II in health and disease.Redox regulation of Nox proteins.Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases.Differential roles of NADPH oxidases in vascular physiology and pathophysiologyNADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury.
P2860
Q24675590-2C5012D7-6E9D-4D68-A852-6660CECFE917Q26861569-68B83E1D-88A7-4685-8B69-5EFA91547F97Q26991619-FCD73D75-1C28-46B4-B26E-286D97C02C36Q27022062-FA2C6840-F876-4033-82FA-3AD6C50094C0Q28576215-13A020FB-14EF-4828-AF7C-EE5C5A606B46Q33599835-07EF78C3-00B9-40EF-A7EE-BE3578D4A751Q33632089-2A2B54E2-4DD7-4B47-910A-B13F5274E853Q33655911-61E68D18-6505-4C2F-A38D-AE349A7BE5C0Q33739287-D157CCDD-47D1-4F70-B12C-FE67D8A5B1CCQ33772560-6D941DEB-4B8E-44FC-8BD9-AC0B2E9D8778Q33772599-178F3B32-A999-4CF3-952A-BD9952F7C783Q33812887-D70A1B66-FF5F-4D58-AC57-25694CF54A58Q33907086-4BCE3EAF-3747-40FA-AD01-E589F4595240Q34001118-B6906BFA-B492-4541-A701-2C5A5681DABCQ34091232-1021C53B-4D22-4408-B745-1C94AEACC53BQ34156155-53258ED3-64B9-4AE4-88F8-9176BDC5AB75Q34897476-DDCE1C0C-393A-492C-A906-0BBF0132F7A3Q35014906-0D9DF462-AD0E-4E0D-BD53-A1D58BB2FDC2Q35101753-0BE257FA-2865-4B88-B1EE-5A5928F9FD42Q35128456-77EEB5D1-D9D0-4C1A-A2FA-C5CC0C328196Q35813861-CDD94926-B52D-4FB1-8BA9-35A4EE37A927Q35867016-FCDD3DCD-EE94-49AF-9E7A-EDF2E4305D71Q36052377-D0A77927-7C77-4483-9681-8C451F459F9CQ36060782-8557DDBF-FB6B-43E9-A8E6-ABC7B2E6B969Q36328374-86DA6823-2230-4F78-A43C-DE12D79E638BQ36444961-D868741F-CD81-428B-A5D3-0177BA7814CBQ36492706-3B73F63B-38D6-4E76-9D73-C8E83B0888CBQ36501270-CAB95B93-72B4-435E-8F46-A3B46245416AQ36741267-6517034E-55BB-4EDD-9DBF-47777B887542Q37063375-1213C627-2227-42A9-98C7-9CCCCDB861B2Q37082781-226DA1D8-994C-4321-969F-4649C00AFCF7Q37138896-5E767626-650D-4E15-B660-0BC335795C90Q37146420-F85C1D40-26F6-41FD-8CC5-DEACB759384DQ37235264-D34FC6D8-1990-471C-B6C6-A9A23D3642B5Q37689190-A6C8893B-1F46-422D-ABC8-02DE5E38D613Q37737495-83098616-3E23-421A-A2FF-27E484150D6CQ37795167-6B00C321-4492-49F4-A453-3957DCAF7AC9Q37838705-1C37C095-0237-4E17-A650-1638144551ECQ37971795-1DD4FA9C-C1CF-4C3C-90D2-011AB94DEFECQ38054458-3C2EBEA6-F214-41D7-8BCF-CECF7EB48FFA
P2860
Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Human urotensin II is a novel ...... ry artery smooth muscle cells.
@ast
Human urotensin II is a novel ...... ry artery smooth muscle cells.
@en
Human urotensin II is a novel ...... ry artery smooth muscle cells.
@nl
type
label
Human urotensin II is a novel ...... ry artery smooth muscle cells.
@ast
Human urotensin II is a novel ...... ry artery smooth muscle cells.
@en
Human urotensin II is a novel ...... ry artery smooth muscle cells.
@nl
prefLabel
Human urotensin II is a novel ...... ry artery smooth muscle cells.
@ast
Human urotensin II is a novel ...... ry artery smooth muscle cells.
@en
Human urotensin II is a novel ...... ry artery smooth muscle cells.
@nl
P2093
P1476
Human urotensin II is a novel ...... ry artery smooth muscle cells.
@en
P2093
Agnes Görlach
Josef Pfeilschifter
Rachida S BelAiba
Steve Bonello
Talija Djordjevic
P304
P356
10.1161/01.ATV.0000154279.98244.EB
P407
P577
2004-12-23T00:00:00Z